In CLL, BIRC3 mutations usually result in the loss of the E3 ubiquitin ligase domain essential for NIK targeting for proteasomal degradation, constitutively activating the non-canonical NF-κB signaling in a ligand-independent manner [10]. This evidence concerns the gene BIRC3 and B-cell chronic lymphocytic leukemia.